Solventum (NYSE:SOLV) Issues Quarterly Earnings Results

Solventum (NYSE:SOLV) issued its earnings results on Wednesday. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64, FiscalAI reports. Solventum had a return on equity of 24.83% and a net margin of 17.26%.The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter last year, the business posted $1.69 EPS. The company’s revenue was up 2.2% compared to the same quarter last year. Solventum updated its FY 2026 guidance to 7.100-7.200 EPS.

Here are the key takeaways from Solventum’s conference call:

• Solventum reported a strong Q2, with 9.5% organic sales growth, adjusted EPS of $2.55, and performance ahead of plan across all segments. Results benefited from approximately $125 million of ERP-related advanced orders and a $100 million tariff refund.
• Management raised 2026 guidance, including organic growth to 2.5%-3% excluding SKU exits (3.5%-4% on an ex-SKU basis), operating margin to 22.2%-22.7%, and EPS to $7.10-$7.20 from $6.40-$6.60.
• The ERP advanced orders are expected to mostly reverse in Q3, creating an anticipated 3%-4% decline in quarterly sales growth and a roughly $0.34 EPS headwind before a projected return to 3%-4% growth in Q4.
• Solventum is advancing the separation of its Health Information Systems business, believing an independent company or combination with a larger healthcare IT player could unlock value while allowing Solventum to focus on MedSurg and Dental. However, the process is still at an early stage and the transaction structure, timing, proceeds, and potential EPS impact remain uncertain.
• Acera continued to outperform, with revenue growth above 40% and gross margin above 80%, while management cited a multi-billion-dollar opportunity from underpenetrated growth drivers, including IV site management, wound care, sterilization, dental aesthetics, and AI-enabled coding.

Solventum Price Performance

SOLV stock traded down $0.22 during midday trading on Friday, reaching $82.74. 296,872 shares of the stock were exchanged, compared to its average volume of 1,412,557. Solventum has a 52 week low of $62.38 and a 52 week high of $90.00. The company has a fifty day moving average price of $79.24 and a 200 day moving average price of $74.38. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The stock has a market capitalization of $14.33 billion, a PE ratio of 10.10, a P/E/G ratio of 1.35 and a beta of 0.60.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q2 results exceeded expectations: Solventum reported adjusted earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue reached $2.21 billion against expectations of $2.15 billion. Organic sales grew 9.5%, despite reported revenue growth of 2.2%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Guidance was raised: Solventum now expects fiscal 2026 adjusted EPS of $7.10-$7.20, above the roughly $6.55-$6.58 analyst consensus, along with improved expectations for organic sales growth and free cash flow. The company also highlighted strong cash generation and share repurchases.
• Positive Sentiment: Portfolio separation could unlock value: Management intends to spin off or otherwise separate its HIS business, allowing Solventum to become a more focused medical-technology company while giving the healthcare software unit greater strategic and investment flexibility. The move addresses activist pressure and may help narrow Solventum’s valuation discount to medical-technology peers. Solventum to hive off healthcare software business, raises profit forecast
• Positive Sentiment: Analyst sentiment improved: Piper Sandler raised its target to $105 and maintained an overweight rating; Wedbush increased its target to $101 with an outperform rating; and Stifel raised its target to $100 with a buy rating. The targets imply roughly 20%-26% upside from recent trading levels.
• Neutral Sentiment: The earnings comparison benefited partly from ERP-related timing effects, and the HIS separation remains subject to execution, regulatory, tax, and transaction risks. Investors will likely focus on the separation timeline and whether organic growth and cash flow remain durable.

Institutional Trading of Solventum

Hedge funds have recently made changes to their positions in the company. BOKF NA raised its position in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Solventum by 23.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 744 shares of the company’s stock valued at $60,000 after buying an additional 142 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Solventum by 1.4% in the 2nd quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock worth $880,000 after buying an additional 163 shares during the period. Orion Porfolio Solutions LLC boosted its holdings in Solventum by 0.7% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company’s stock worth $1,843,000 after buying an additional 176 shares during the period. Finally, Lido Advisors LLC grew its stake in Solventum by 2.3% in the 4th quarter. Lido Advisors LLC now owns 7,899 shares of the company’s stock valued at $583,000 after buying an additional 178 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SOLV. Wedbush upped their price objective on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research report on Thursday. Stifel Nicolaus raised their price objective on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group lifted their target price on Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday. BMO Capital Markets began coverage on Solventum in a research note on Wednesday, July 8th. They set a “market perform” rating and a $81.00 target price for the company. Finally, BTIG Research increased their target price on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and a consensus price target of $91.64.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.